Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV mRNA vaccine (Virogin Biotech)
- Development stage
- Preclinical
- Lead developer
- Virogin Biotech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Virogin Biotech is developing a therapeutic mRNA vaccine targeting the Epstein-Barr virus (EBV) for the treatment of EBV-positive tumors. The vaccine candidate is part of Virogin's discovery-stage mRNA platform, which utilizes both conventional mRNA and self-amplifying RNA (saRNA) technologies. This approach is designed to elicit robust immune responses against EBV antigens expressed in EBV-associated malignancies. The vaccine is currently in the IND-enabling stage of development. Virogin Biotech maintains worldwide rights to the candidate and leverages a partnership with CNBG, a subsidiary of Sinopharm, for large-scale manufacturing capabilities.
- Other names
- EBV mRNA vaccineVirogin EBV mRNA vaccine
02
Targets
gB (Human cytomegalovirus glycoprotein B)gp350 (Epstein-Barr virus glycoprotein 350)EBV gH/gL (Epstein-Barr virus glycoprotein H/glycoprotein L complex)gL (Epstein-Barr virus glycoprotein L)
Beyond the preview
Go deeper on EBV mRNA vaccine (Virogin Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV mRNA vaccine (Virogin Biotech).